
Labcorp selected for biomarker testing in Florida prostate-cancer study
OTraces plans to test about 950 men under a US$2M state grant that ends in March 2027; Labcorp's fee is undisclosed.

OTraces plans to test about 950 men under a US$2M state grant that ends in March 2027; Labcorp's fee is undisclosed.

The company describes 36 allowed claims for twice-daily treatment, with formal patent issuance scheduled for Nov. 24.

The pooled Phase 2 analysis covers 43 evaluable patients, while a randomized Phase 3 survival analysis is planned for 2027.



The exploratory VENTURE findings add cardiometabolic measures while weight-loss and tolerability data were previously disclosed.
New controlled event rates expand the avexitide readout, while the company still targets a year-end FDA application.
The applications follow a Phase 3 trial showing 27 per cent fewer painful crises versus placebo, with regulatory action expected in 2027.
Twelve participants stopped intravenous glucose, while final statistics are due in December and a US$100M offering is expected to close Nov. 16.
The 26-patient trial supports a priority review request, but the Nov. 12 release gives no FDA acceptance date or decision deadline.
New breast and lung cancer applications aim to inform therapy choices when conventional mutation markers leave gaps.
Weekly brelovitug achieved a 59 per cent combined response, and Mirum plans an FDA filing in the first half of 2027.
Eight participants completed the placebo-controlled cohort; extension data are expected in January 2027 while a partial FDA hold remains.
The 86 per cent brain-response rate came from seven evaluable patients; lower-dose safety data are required before Phase 3.
The 370-patient randomized trial supports a planned year-end FDA filing, but response rates and detailed safety data remain undisclosed.
Lorundrostat's extension study showed a 17.8 mmHg reduction from baseline as an FDA decision approaches on Dec. 22.
The delayed-treatment arm recorded no responses, while Vir plans an FDA submission in mid-2027 after two further pivotal readouts.
New Phase 1/2 data cover durability across three autoimmune diseases and safety in 71 patients treated after preconditioning.
At week 16, 58 per cent achieved the main joint response versus 41 per cent on placebo; the oral drug is not approved for psoriatic arthritis.
MRI-measured muscle fat fraction replaces dynamometry in the 53-boy Duchenne study, with placebo-controlled data expected in Q1 2027.
Armenia's conditional authorizations cover previously treated metastatic colorectal cancer; existing financing supports operations into 2027.
The 353-patient VOCAL study tested three-times-weekly vadadustat, a regimen that remains investigational despite Vafseo's daily-use approval.
Collection succeeded in 94.7 per cent of patients, but the retrospective analysis measures feasibility rather than comparative cancer outcomes.
Sensitivity was slightly lower than standard ECGs; a U.S. pivotal study is planned for the first quarter of 2027.
The agency cited mouse toxicity and inadequate data for pediatric enrollment; the company is awaiting its full clinical hold letter.
The agency set a May 1, 2027 action target for AMT-130 and is tentatively planning an advisory committee meeting.
The combination beat pembrolizumab alone on survival and tumour response in first-line PD-L1-positive head-and-neck cancer.
A planned 72-participant study will test four subcutaneous doses, with safety and tolerability assessed over 48 weeks.
The 523-patient study met its progression-free survival endpoint, but Pfizer withheld the comparative effect size and a filing date.
A pooled analysis of 139 treated adults showed sustained filtration gains, but long-term follow-up had no continuing placebo comparison.
Class C certification supports continued EU access beyond the 2028 transition deadline and covers the quality management system.
Four of 16 evaluable patients responded to lorigerlimab as the company enrols a lower-dose cohort after significant treatment-related toxicity.
RESOLVE will test symptom recovery and hospitalization in high-risk adults, starting with at least 200 patients in its Phase 2b portion.
The 541-patient DYNASTY-Breast02 trial met its primary endpoint, but the partners say potential patient benefit is limited.
Ivonescimab plus chemotherapy extended median survival to 14.9 months in a China-only study, with a separate U.S. trial planned.
Pumitamig plus docetaxel showed early activity after immunotherapy and chemotherapy, but the Phase 2 study had no control arm.
Severe or worse treatment-related adverse events affected 72.1 per cent across expansion cohorts; FDA talks are planned for 2027.
The single-arm analysis includes unconfirmed responses and supports two enrolling Phase 3 trials; median response duration was not disclosed.
The uncontrolled first-line analyses support continued development, with randomized SUNRAY-01 results expected in the first half of 2027.